{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["170(3)"],"submitter":["Katzendobler S"],"funding":["Klinikum der Universität München"],"pubmed_abstract":["<h4>Background</h4>Survival times of patients with IDH-mutant gliomas are variable and can extend to decades. Many studies provide progression-free rather than overall survival times and prognostic factors remain ill-defined. Here we explored characteristics of short- and long-term survivors within a cohort of patients with extended follow-up.<h4>Methods</h4>This single-center, case-control study included 86 patients diagnosed between 1998 and 2023 who either died within 6 years after diagnosis or survived at least 15 years. Patient characteristics and prognostic factors were stratified by short- (< 6 years) versus long-term (≥ 15 years) survival.<h4>Results</h4>Forty-seven patients (55%) diagnosed with astrocytoma and 39 patients (45%) with oligodendroglioma were included retrospectively."],"journal":["Journal of neuro-oncology"],"pagination":["655-664"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11614945"],"repository":["biostudies-literature"],"pubmed_title":["Determinants of long-term survival in patients with IDH-mutant gliomas."],"pmcid":["PMC11614945"],"pubmed_authors":["Weller M","Thon N","von Baumgarten L","Blobner J","Katzendobler S","Niedermeyer S","Harter PN","Tonn JC","Stoecklein VM","Trumm C","Weller J"],"additional_accession":[]},"is_claimable":false,"name":"Determinants of long-term survival in patients with IDH-mutant gliomas.","description":"<h4>Background</h4>Survival times of patients with IDH-mutant gliomas are variable and can extend to decades. Many studies provide progression-free rather than overall survival times and prognostic factors remain ill-defined. Here we explored characteristics of short- and long-term survivors within a cohort of patients with extended follow-up.<h4>Methods</h4>This single-center, case-control study included 86 patients diagnosed between 1998 and 2023 who either died within 6 years after diagnosis or survived at least 15 years. Patient characteristics and prognostic factors were stratified by short- (< 6 years) versus long-term (≥ 15 years) survival.<h4>Results</h4>Forty-seven patients (55%) diagnosed with astrocytoma and 39 patients (45%) with oligodendroglioma were included retrospectively.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2026-06-03T03:17:02.747Z","creation":"2025-04-04T01:23:41.848Z"},"accession":"S-EPMC11614945","cross_references":{"pubmed":["39316316"],"doi":["10.1007/s11060-024-04826-9"]}}